Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : T/FIF Portfolio -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (699)	3/15/1999 10:02:00 PM
From: mike head	Respond to of 1073

Nice news today on ABGX, which I think our host likes... Pre-clinical, but what the Hell! Pax et Bonum, mch

To: scaram(o)uche who wrote (699)	3/16/1999 9:28:00 AM
From: BRAVEHEART	Read Replies (1) \| Respond to of 1073

"PRIME" TIME... I'm sure this article has been tossed around more than once...Let's give it one more critique in light of the last paragraph in anticipation of the potential it may point out. "A number of angiogenesis inhibitors that predate the discovery of angiostatin and endostatin are in early stages of tests in human cancer patients, but little information about the results has been released by the companies carrying them out. Reports are likely to be aired this spring." boston.com Does anyone have a short list of companies with the promise of producing "large quantities of angiostatin and endostatin". This process was stimulated by a release today by GMED. ''We are very pleased to be able to announce our second program to enter human clinical trials through our collaboration with Roche,'' stated Norman Hardman, Ph.D., president and chief operating officer of GeneMedicine. ''We are also encouraged that our IFN-alpha and IL-2 gene medicines appear to overcome the limitations of the currently available recombinant cytokine products. By delivering genes directly to the tumors and minimizing systemic exposure while retaining a systemic immune response, we hope to create cancer treatments with fewer side effects. In addition, in preclinical and early Phase I studies, our gene medicines have demonstrated sustainable, therapeutically relevant levels of protein production, appearing to solve the short half-life problems associated with the recombinant cytokines. Specifically, preclinical data on the IFN-alpha gene medicine were recently published showing both local and systemic immune response against tumor.'' biz.yahoo.com Any comments on GMED's approach to genetherapy... "The Company's core technology includes lipid-, polymer-, and peptide-based gene delivery systems, each able to be applied to specific clinical targets, and gene expression systems to regulate the production of multiple genes." "In contrast, the IFN-alpha gene medicine is designed for both local and systemic immunotherapy and also has been shown to provide anti-angiogenic effect in preclinical cancer models." Does anyone else know of any other companies R&D ing interferon under a gene therapy protocal??? Thanks Jeffrey